Gut Imaging for Function & Transit in Cystic Fibrosis Study 2
Status:
Completed
Trial end date:
2020-10-29
Target enrollment:
Participant gender:
Summary
People with Cystic Fibrosis (CF) have problems digesting their food properly. More than 8 in
10 people with CF must take medication to assist their digestion. In spite of this,
complications such as bowel blockage occur.
Finding out how already licenced drugs for CF work in the gut is the first step in
repurposing medications. Tezacaftor/Ivacaftor with Ivacaftor is a drug combination which
corrects the basic defect in CF an has shown improvements on lung function.
The purpose of this study is to evaluate, using Magnetic Resonance Imaging (MRI) and
patient-reported outcomes, whether Tezacaftor/Ivacaftor with Ivacaftor has an effect on
improving gastrointestinal problems in CF.
Phase:
Phase 2
Details
Lead Sponsor:
Nottingham University Hospitals NHS Trust
Collaborators:
Cystic Fibrosis Foundation Cystic Fibrosis Trust Nottingham University Hospitals Charity University of Nottingham Vertex Pharmaceuticals Incorporated